199 related articles for article (PubMed ID: 21435405)
1. Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.
Orlandi F; Guevara-Patiño JA; Merghoub T; Wolchok JD; Houghton AN; Gregor PD
Vaccine; 2011 May; 29(20):3646-54. PubMed ID: 21435405
[TBL] [Abstract][Full Text] [Related]
2. CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.
Nguyen-Hoai T; Hohn O; Vu MD; Baldenhofer G; Sayed Ahmed MS; Dörken B; Norley S; Lipp M; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Dec; 19(12):880-7. PubMed ID: 23099886
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
Eralp Y; Wang X; Wang JP; Maughan MF; Polo JM; Lachman LB
Breast Cancer Res; 2004; 6(4):R275-83. PubMed ID: 15217493
[TBL] [Abstract][Full Text] [Related]
5. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
6. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
[TBL] [Abstract][Full Text] [Related]
7. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
[TBL] [Abstract][Full Text] [Related]
8. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.
Garrett JT; Rawale S; Allen SD; Phillips G; Forni G; Morris JC; Kaumaya PT
J Immunol; 2007 Jun; 178(11):7120-31. PubMed ID: 17513761
[TBL] [Abstract][Full Text] [Related]
9. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.
Mittendorf EA; Storrer CE; Shriver CD; Ponniah S; Peoples GE
Ann Surg Oncol; 2006 Aug; 13(8):1085-98. PubMed ID: 16865596
[TBL] [Abstract][Full Text] [Related]
10. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu.
Riemer AB; Klinger M; Wagner S; Bernhaus A; Mazzucchelli L; Pehamberger H; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Immunol; 2004 Jul; 173(1):394-401. PubMed ID: 15210798
[TBL] [Abstract][Full Text] [Related]
11. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
Whittington PJ; Piechocki MP; Heng HH; Jacob JB; Jones RF; Back JB; Wei WZ
Cancer Res; 2008 Sep; 68(18):7502-11. PubMed ID: 18794138
[TBL] [Abstract][Full Text] [Related]
13. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
Park JM; Terabe M; Steel JC; Forni G; Sakai Y; Morris JC; Berzofsky JA
Cancer Res; 2008 Mar; 68(6):1979-87. PubMed ID: 18339880
[TBL] [Abstract][Full Text] [Related]
14. CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Nguyen-Hoai T; Baldenhofer G; Sayed Ahmed MS; Pham-Duc M; Vu MD; Lipp M; Dörken B; Pezzutto A; Westermann J
Cancer Gene Ther; 2012 Jan; 19(1):69-76. PubMed ID: 21997231
[TBL] [Abstract][Full Text] [Related]
15. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.
Cho HI; Niu G; Bradley N; Celis E
Cancer Immunol Immunother; 2008 Nov; 57(11):1695-703. PubMed ID: 18253731
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of rat-neu
Sow HS; Benonisson H; Brouwers C; Linssen MM; Camps M; Breukel C; Claassens J; van Hall T; Ossendorp F; Fransen MF; Verbeek JS
Sci Rep; 2020 Mar; 10(1):3933. PubMed ID: 32127568
[TBL] [Abstract][Full Text] [Related]
17. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
[TBL] [Abstract][Full Text] [Related]
18. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
19. CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.
Nguyen-Hoai T; Pham-Duc M; Gries M; Dörken B; Pezzutto A; Westermann J
Cancer Gene Ther; 2016 Jun; 23(6):162-7. PubMed ID: 27056671
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma.
Smorlesi A; Papalini F; Amici A; Orlando F; Pierpaoli S; Mancini C; Provinciali M
Vaccine; 2006 Mar; 24(11):1766-75. PubMed ID: 16288939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
